DBV Technologies (NASDAQ:DBVT) Shares Gap Up – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $20.00, but opened at $20.85. DBV Technologies shares last traded at $19.5350, with a volume of 161,540 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on DBVT shares. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday. Guggenheim initiated coverage on DBV Technologies in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $35.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target (up previously from $16.00) on shares of DBV Technologies in a research note on Wednesday, October 29th. Finally, Zacks Research raised DBV Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, DBV Technologies has a consensus rating of “Moderate Buy” and an average target price of $20.81.

DBV Technologies Price Performance

The company has a market capitalization of $753.10 million, a P/E ratio of -3.75 and a beta of -1.10. The stock’s 50 day moving average is $14.55 and its 200-day moving average is $11.29.

Institutional Investors Weigh In On DBV Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund bought a new stake in shares of DBV Technologies in the third quarter worth about $34,000. Two Sigma Investments LP bought a new stake in DBV Technologies in the third quarter worth about $167,000. Citadel Advisors LLC bought a new stake in shares of DBV Technologies during the third quarter worth $220,000. DLD Asset Management LP bought a new position in DBV Technologies in the 3rd quarter worth about $250,000. Finally, Nan Fung Trinity HK Ltd. purchased a new position in DBV Technologies during the 2nd quarter worth $340,000. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.